ScripBiologics contract development and manufacturing organizations (CDMO) have emerged as top merger and acquisition targets in the global biopharma industry and South Korean firms are actively taking par
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Astellas/Xyphos And GO Target Glycoprot
ScripWhile global pharma firms are rolling out advanced gene and cell therapies, as well as aggressively making R&D investments in the space to grab the leading position in the burgeoning market, South Kor
Pink SheetAdding to a number of cutting-edge biologics that have been approved in South Korea this year, the country has just given regulatory clearance to the first study with a regenerative medicine under new